Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mismatch Repair01:20

Mismatch Repair

7.2K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
7.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Polygenic risk score with KLK3 SNP-SNP interaction pairs for predicting prostate cancer aggressiveness.

Communications medicine·2026
Same author

Germline polygenic score for prostate cancer aggressiveness.

medRxiv : the preprint server for health sciences·2026
Same author

Myosteatosis and Sarcopenic Obesity in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: Rationale for Mechanism-Driven Multimodal Intervention.

Cancers·2026
Same author

Phase II trial of combination radiation, hormone, and immunotherapy in grade group 5 prostate cancer.

Journal for immunotherapy of cancer·2026
Same author

Genomic Analysis of Puerto Rican Hispanic/Latino Men with Prostate Cancer.

Cancers·2026
Same author

Novel Voxel-Based MRI Risk Score LADCT<sub>2</sub> as a Tool for Prediction of Prostate Cancer: A Proof of Concept With Retrospective Study.

Cancer control : journal of the Moffitt Cancer Center·2026

Related Experiment Video

Updated: Apr 20, 2026

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis
10:40

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis

Published on: April 25, 2022

3.0K

CHEK2 (∗) 1100delC Mutation and Risk of Prostate Cancer.

Victoria Hale1, Maren Weischer2, Jong Y Park1

  • 1Department of Cancer Epidemiology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA.

Prostate Cancer
|November 29, 2014
PubMed
Summary

The CHEK2 (∗)1100delC genetic variant significantly increases prostate cancer risk, particularly in familial cases. Genetic screening for this variant is recommended for men with a family history of prostate cancer.

More Related Videos

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

17.3K
Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq
09:52

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq

Published on: April 19, 2013

25.0K

Related Experiment Videos

Last Updated: Apr 20, 2026

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis
10:40

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis

Published on: April 25, 2022

3.0K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

17.3K
Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq
09:52

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq

Published on: April 19, 2013

25.0K

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Prostate cancer etiology is multifactorial, with genetic predisposition playing a significant role.
  • The CHEK2 gene is crucial for DNA replication and repair, responding to double-strand breaks.
  • Understanding specific genetic variants like CHEK2 (∗)1100delC is vital for risk assessment.

Purpose of the Study:

  • To review current knowledge on the association between the CHEK2 (∗)1100delC variant and prostate cancer risk.
  • To discuss the clinical implications of this genetic variant in prostate cancer.
  • To synthesize evidence from existing studies on CHEK2 (∗)1100delC and prostate cancer.

Main Methods:

  • Systematic review of published literature.
  • Identification of studies investigating the CHEK2 (∗)1100delC variant and prostate cancer.
  • Meta-analysis of pooled data from eligible studies.

Main Results:

  • Twelve articles were identified, with five providing independent data for conclusive analysis.
  • The CHEK2 (∗)1100delC mutation showed a pooled odds ratio (OR) of 1.98 (95% CI: 1.23-3.18) for unselected prostate cancer cases.
  • A higher pooled OR of 3.39 (95% CI: 1.78-6.47) was observed for familial prostate cancer cases.

Conclusions:

  • The CHEK2 (∗)1100delC genetic variant is associated with an elevated risk of developing prostate cancer.
  • The association is more pronounced in individuals with a familial history of the disease.
  • Genetic screening for CHEK2 (∗)1100delC may be beneficial for men with a family history of prostate cancer.